Clinical trial
Daclizumab to Treat Chronic Immune Thrombocytopenia
NCT00049725 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00049725 |
|---|---|
| Title | Daclizumab to Treat Chronic Immune Thrombocytopenia |
| Official title | A Study of Daclizumab in Chronic Immune Thrombocytopenia (ITP) |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thrombocytopenia |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 24 |
| Start date | Nov 1, 2002 |
| Completion | Dec 1, 2004 |
| First posted | Nov 13, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: